Ali Behbahani, Director at Black Diamond Therapeutics, Inc. (BDTX), bought 1,000,000 shares at $5.00 ($5.0M) on 2023-07-05, disclosed to the SEC on 2023-07-06.
Open-market purchase of $5.0M BDTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ADAP | SELL | 2025-08-19 | $342K | — | Filing → |
| MBX | BUY | 2024-09-17 | $8.0M | — | Filing → |
| SVRA | BUY | 2023-07-19 | $1000K | — | Filing → |